Manufacturing CAR-NK against tumors: Who is the ideal supplier?
Authors:
- 1 January 2024
- journal article
- review article
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 36 (1) , 1-16
Abstract
Chimeric antigen receptor-natural killer (CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice. However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.Keywords
This publication has 125 references indexed in Scilit:
- Efficient gene transfer into primary human natural killer cells by retroviral transductionExperimental Hematology, 2005
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cellsBlood, 2004
- Identification of a Novel Subpopulation of Human Cord Blood CD34−CD133−CD7−CD45+Lineage− Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15The Journal of Immunology, 2003
- Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapyCytotherapy, 2003
- The biology of human natural killer-cell subsetsTrends in Immunology, 2001
- Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92Journal of Hematotherapy & Stem Cell Research, 2001
- Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.1996
- Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.1994
- HEMATOLOGIC EFFECTS OF IMMUNOTHERAPY WITH LYMPHOKINE-ACTIVATED KILLER-CELLS AND RECOMBINANT INTERLEUKIN-2 IN CANCER-PATIENTS1987